Clinical trials: Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
The purpose of this study is to test the safety and efficacy (benefits) of an investigational drug LB-100, for treatment of myelodysplastic syndromes. LB-100 has previously been administered to patients with various solid tumors.
- Trial name
- NCT03886662
- Testing
- LB-100
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Lixte Biotechnology Holdings, Inc.
Myelodysplastic Syndrome
Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS
This is a Phase II, open-label clinical trial examining the role of Panhematin® in patients with MDS. The objective of this study is to evaluate the safety and efficacy of Panhematin® (hematin for injection) in the treatment of…
- Trial name
- NCT00467610
- Testing
- Panhematin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Rush University Medical Center
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL)
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant.
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome)
- Trial name
- ACCELERATE (NCT06859424)
- Testing
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C
- Where
- 13 sites in United States
- Volunteers
- 358 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Myelodysplastic Syndrome, Acute Myeloblastic Leukemia
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients
Primary Objective: 1. To assess the self-reported symptoms and the plasma cytokine levels of AML/MDS patients pretransplantation and posttransplantation with allogeneic blood and marrow in order to identify changes in symptoms…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloblastic Leukemia, Leukemia
- Trial name
- NCT00504920
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Acute Disease
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML
- Conditions
- Leukemia, Acute Disease, Acute Myeloid Leukemia, Nonlymphocytic Leukemia
- Trial name
- NCT00607997
- Testing
- vosaroxin
- Where
- 20 sites in United States
- Volunteers
- 113 people
- Sponsor
- Sunesis Pharmaceuticals
Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of ASTX029 that can be given in combination with ASTX727 to participants who have RAS-mutant MDS or MDS/MPN.
- Conditions
- Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
- Trial name
- NCT06284460
- Testing
- ASTX029, ASTX727
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML)…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT01399840
- Testing
- BMN 673
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Pfizer
Myelodysplastic Syndrome, Acute Myeloid Leukemia
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
A non-randomized phase Ib study of PC14586 (PMV therapeutics) in patients diagnosed with TP53Y220C-mutant myeloid malignancies, including AML and MDS.
- Trial name
- NCT06616636
- Testing
- Azacitidine, Rezatapopt
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
The purpose of this study is to demonstrate that epoetin alfa works better than placebo in improving anemia in patients with lower-risk myelodysplastic syndromes (MDS). The safety of epoetin alfa will also be evaluated.
- Trial name
- NCT01381809
- Testing
- Group 1: Epoetin alfa
- Where
- 28 sites in Bulgaria, France and 3 more
- Volunteers
- 130 people
- Sponsor
- Janssen-Cilag International NV
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndrome (MDS)
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral…
- Trial name
- NCT04878432
- Testing
- MBG453, Azacitidine, Decitabine
- Where
- 15 sites in United States
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
This study will examine the safety of clofarabine, TLI and ATG as a reduced conditioning regimen prior to allogeneic transplantation.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00697684
- Testing
- Antithymocyte Globulin, Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Beth Israel Deaconess Medical Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
In this research study, our main goal for the ipilimumab portion of the study is to determine the highest dose of ipilimumab that can be given safely in several courses and to determine what side effects are seen in patients with…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03912064
- Testing
- Ipilimumab, CD25hi Treg depleted DLI
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
The purpose of this phase I/II study is to define the maximum tolerated dose of 5-AzaC and the effect on grade II-IV GvHD when given after matched unrelated donor transplant (MUD).
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT01747499
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Washington University School of Medicine
Hematologic Diseases
Progression of Hematopoietic Diseases in Shanghai, China
The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures…
- Trial name
- NCT00365014
- Where
- China
- Volunteers
- 10,757 people
- Sponsor
- University of Colorado, Denver
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
This phase II trial is studying the side effects and how well giving fludarabine phosphate, busulfan, anti-thymocyte globulin followed by donor peripheral blood stem cell transplant, tacrolimus, and methotrexate works in treating…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01056614
- Testing
- fludarabine phosphate, busulfan, anti-thymocyte globulin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndrome, Anemia in Myelodysplastic Syndromes
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
This research is being conducted to asses if HT-6184 is effective in the treatment of Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia.
- Trial name
- NCT07052006
- Testing
- HT-6184
- Where
- 10 sites in India
- Volunteers
- 37 people
- Sponsor
- Halia Therapeutics, Inc.
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory).
- Conditions
- Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04220684
- Testing
- Cytarabine Hydrochloride, Fludarabine, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Sumithira Vasu
Myelodysplastic Syndrome
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
This is a phase II study of lenalidomide in patients with myelodysplastic syndrome (MDS) and with acute myeloid leukemia (AML) with trilineage dysplasia. Patients will receive two cycles of lenalidomide.
- Trial name
- NCT00867308
- Testing
- Lenalidomide 50 mg, Lenalidomide 15 mg
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hemoglobinopathies, Myelodysplastic Syndromes
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
This study will evaluate the change in cardiac iron load over a 53 week period measured by MRI in 2 cohorts of patients
- Conditions
- Hemoglobinopathies, Myelodysplastic Syndromes, Other Inherited or Acquired Anaemia, MPD Syndrome
- Trial name
- NCT00673608
- Testing
- deferasirox
- Where
- 4 sites in Australia
- Volunteers
- 118 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.